logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Yum China (09987) spent HK$7.72 million on March 10 to repurchase 18,600 shares.

date
18:22 11/03/2026
avatar
GMT Eight
China's Bright Food Group (09987) announced that on March 10, 2026, the company repurchased 18,600 shares at a cost of 7.7216 million Hong Kong dollars.
Yum China (09987) announced that on March 10, 2026, the company spent 7.7216 million Hong Kong dollars to repurchase 18,600 shares.
Related Articles
China Stock
Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.
China Stock
East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.
HK Stock
SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.
Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.
China Stock
East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.
China Stock
SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.
HK Stock
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
icon
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
icon
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
icon
11/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.